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Available online 22 January 2016The global burden of ischaemic strokes is almost 4-fold greater than haemorrhagic strokes. Current evi-
dence suggests that 25–30% of ischaemic stroke survivors develop immediate or delayed vascular cognitive
impairment (VCI) or vascular dementia (VaD). Dementia after stroke injury may encompass all types of
cognitive disorders. States of cognitive dysfunction before the index stroke are described under the umbrel-
la of pre-stroke dementia, which may entail vascular changes as well as insidious neurodegenerative pro-
cesses. Risk factors for cognitive impairment and dementia after stroke are multifactorial including older
age, family history, genetic variants, low educational status, vascular comorbidities, prior transient ischae-
mic attack or recurrent stroke and depressive illness. Neuroimaging determinants of dementia after stroke
comprise silent brain infarcts, white matter changes, lacunar infarcts and medial temporal lobe atrophy.
Until recently, the neuropathology of dementia after stroke was poorly defined. Most of post-stroke demen-
tia is consistent with VaD involving multiple substrates. Microinfarction, microvascular changes related to
blood–brain barrier damage, focal neuronal atrophy and low burden of co-existing neurodegenerative pa-
thology appear key substrates of dementia after stroke injury. The elucidation of mechanisms of dementia
after stroke injury will enable establishment of effective strategy for symptomatic relief and prevention.
Controlling vascular disease risk factors is essential to reduce the burden of cognitive dysfunction after
stroke. This article is part of a Special Issue entitled: Vascular Contributions to Cognitive Impairment and
Dementia edited by M. Paul Murphy, Roderick A. Corriveau and Donna M. Wilcock.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Stroke as the third leading cause of death is considered an important
cause of long-term disability and cognitive impairment. This demands
enormous resources from healthcare systems [1]. The incidence of
stroke varies greatly according to the age structure of the population
under study. The age-adjusted annual incidence of all first-time strokes
in different countries has changed considerably over the last four de-
cades (1970–2010) [2,3] Stroke incidence in the UK has decreased and
survival after stroke has improved in the past 10 years. [4] Improved
drug treatment in primary care is likely to be a major contributor to
this, with better control of risk factors both before and after incident
stroke. The increasing incidence of stroke in low to middle income
countries over the past four decades is likely explained by health and
demographic transitions in these countries [5]. However, the globallar Contributions to Cognitive
derick A. Corriveau, and Donna
e, NIHR Biomedical Research
ad, Newcastle upon Tyne, NE4
. This is an open access article underburden of stroke is likely underestimated by not accounting for silent
strokes, transient ischaemic attacks in many cases, vascular dementia
(VaD) and long term stroke related disability in case definition.
Deaths from stroke have declined in high-income countries and
many middle- and low-income countries. The key element in this de-
cline is reduced incidence of stroke [2] but the case fatality rates have
also decreased due to either lesser stroke severity or improvedmanage-
ment [6]. Although age-standardised rates of stroke mortality have de-
creased worldwide in the past two decades, the absolute number of
people who have a stroke every year, stroke survivors, related deaths,
and the overall global burden of stroke (DALYs lost) are increasing
with most of the burden in low-income and middle-income countries.
The most striking increases in the number of stroke survivors (113%),
DALYs lost (31%), and stroke-related deaths (36%) were in people
aged 75 years and older. Increasing age is the strongest risk factor for
stroke throughout the lifespan. The steep increases in incidence with
age occur in both men and women. While the risk for a child under
15 years of age is 1 in 100 000, it is 1 in 33 for people aged 85 years
and over. Stroke incidence more than doubles every decade after the
age of 55 years until 84 years and beyond [7]. In the Oxford vascular
study, stroke rates increased from 1.8/1000 individuals per year for
55–64 year olds to 17 for those aged 85 or older [8]. High blood pressurethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
916 R.N. Kalaria et al. / Biochimica et Biophysica Acta 1862 (2016) 915–925is the most treatable risk factor for both ischaemic and haemorrhagic
strokes. It presents a golden opportunity for prevention and reducing
the burden of stroke and post-stroke cognitive impairment.
2. Stroke types contributing to impairment
The clinical diagnosis of stroke is usually accurate but the precise
type of stroke and exact localizationmay be less straightforward. Deter-
mination of the pathological type of stroke is best achieved by early
brain imaging usually computed tomography (CT) or by autopsy confir-
mation. In western countries, cerebral infarction accounts for approxi-
mately 80% of first-time strokes, and parenchymal brain haemorrhage
for 20%. In Africa, however, the burden of haemorrhagic strokes are re-
ported to be significantly greater by more than 10% at a ratio of 66:34
ischaemic to haemorrhagic [9]. According to the recent updated defini-
tions of the Stroke Council of the American Heart Association/American
Stroke Association [10], the relative frequencies and subtypes of ischae-
mic and haemorrhagic infarctions may be (1) atherothrombotic, due to
either (1 A) large artery thrombosis or (1B) artery-to-artery embolism;
(2) cardioembolic; and (3) lacunar. The limitations of even the most ad-
vanced imaging techniques can be recognised by the inclusion of (4) in-
farcts of undetermined cause [11]. In infarcts of known cause, the lumen
of intracranial large tomedium-sized arteries ismost commonly occluded
by an embolus [10]. The frequency of locally formed thrombi in these ar-
teries proved to be much lower than had been estimated previously. In
contrast, a local processmost often occludes small intraparenchymal pen-
etrating arteries: thrombosis of a diseased small artery,microatheroma or
microemboli from an atherosclerotic plaque occluding the origin of a
penetrating artery [12]. The presence of microemboli in retinal arteries
provides indirect evidence that microemboli may also enter small-
calibre intracerebral penetrating arteries. However, more recent recom-
mendations [13,14] highlight that besides distinguishing the main
aetiological categories including atherothrombotic, cardioembolic,
small vessel disease and other rarer causes, aetiological classification
of stroke should reflect the most likely cause without neglecting other
vascular conditions that may co-exist. For example, small vessel disease
often occurs in the presence of severe large vessel obstruction [12,15].
3. Stroke and dementia: definitions and criteria
Dementia developing after stroke is thought to be a clinical entity to
define any type of dementia occurring subsequent to stroke injury irre-
spective whether it involves vascular, neurodegenerative or mixed pro-
cesses. It can therefore entail a complex aetiology with varying
combinations of large and small vessel disease as well as non-vascular
neurodegenerative pathology. The development of dementia after
stroke depends on several factors including the location and volumeFig. 1. Localization of infarcts or tissue changes associatedwith development of dementia after st
from large vessel occlusion (atherothromboembolism), artery-to-artery embolism or cardio
hypertensive, arteriosclerotic, amyloid or collagen angiopathy. Subtype III is caused by infarct
risk factors including cardioembolism and intracranial small vessel disease. Shaded areas
microinfarcts, although the size of the latter can only be appreciated from microscopical ima
for the three subtypes are as follows: Subtype I, 20–40%; subtype II, 40–50% and subtype III
hypertension, carotid artery disease or atherosclerosis, cardio embolism (mostly atrial fibrillat
hyperlipidaemia, hyperhomocysteinaemia, chronic kidney disease, infection and obstructiv
factors. These subtypes would include dementia among post-stroke survivors who fulfil the N
la Recherché et l'Enseignement en Neurosciences (NINDS-AIREN) criteria for probable vasculaof the stroke, degree of related neuronal damage, presence of pre-
existing cognitive impairment or other cerebral pathology. The direct
influence of any specific genetic factor(s) is not clear. However, the her-
itability estimate for all ischaemic strokeswas determined to be 38% but
varied considerably by subtype with the greatest associated with large
vessel (40%) and cardioembolic disease (33%) and lowest with small
vessel disease (16%) [16].
Cognitive impairment or dementia after stroke is predominantly de-
fined by dementia that occurredwithin threemonths after stroke onset.
Irrespective, many stroke survivors develop delayed dementia beyond
threemonths or only after recurrent stroke(s). The recognition of cogni-
tive impairment in the acute phase after strokemay offer vital informa-
tion to the clinician for early cognitive rehabilitation [17] and
preventing early fatality by improved management [18].
Recent prospective studies suggest stroke survivors may unmask or
trigger varied pathologies including those attributed to subcortical VaD,
multi-infarct dementia and even strategic infarct dementia [19–21] (Fig.
1). Given this definition,most cases of dementia after strokemay be de-
scribed under the umbrella termof vascular cognitive impairment (VCI)
[22,23], which is introduced to incorporate the full spectrum of cogni-
tive changes related to all causes of vascular disease from VCI no-
dementia to frank dementia of vascular origin. It is suggested that dys-
function of the neurovascular unit and mechanisms regulating cerebral
blood flow particularly in the deep white matter (WM) are important
components of the pathophysiological processes underlying VCI. The
continuum of VCI is also discussed broadly under the rubric of vascular
cognitive disorders (VCDs) [24], which comprise many diseases, each
with varying severity and patterns of dysfunction. The categorical diag-
nosis of VCDs encompasses mild impairment, pre-dementia, and de-
mentia syndrome, and major VCD category is equivalent to dementia
as adopted in the DSM-5 criteria. Overall, dementia after stroke fits
the categorization of severe VCD [24]. (See Fig. 2.)
The cognitive domains involved in the development of dementia
after stroke may also vary depending on stroke characteristics such as
stroke type, volume, numbers, location and severity. Regarding the
stroke type, patients with ischemic strokes usually have higher survival
rates than do those with hemorrhagic strokes, which explains why is-
chemic strokes lead to psychiatric morbidity more frequently than do
hemorrhagic strokes [25]. Important critical locations also include dom-
inant hemisphere and lesions affecting the prefrontal–subcortical cir-
cuit that mediates executive dysfunction [26,27]. Frontal lobe
functions comprising processing speed, reaction time, workingmemory
and executive task measures are most affected [28]. A single large
cortico-subcortical brain ischemic lesion, if located in an area that is
functionally critical for cognition, may present with acute cognitive de-
terioration. Strategic infarct dementia is attributed to locations in the
angular gyrus, the medial frontal lobe, and the inferomedial portion ofroke. Dementia associatedwith different cerebrovascular pathologies. Subtype Imay result
embolism. Subtype II usually involves descriptions of arteriolosclerosis, lipohyalinosis,
s in the ‘strategic’ areas such as the thalamus and hippocampus and may involve several
in each outline coronal show locations of lesions. Small dots depict small infarcts and
ges. Currently reported studies (and unpublished data) show that the estimated % cases
, 10–15%. The risk factors associated with particularly Subtype I can be varied including
ion) and coronary artery disease. Subtype II may involve hypertension, diabetes mellitus,
e sleep aponea. Lifestyle factors such as smoking, obesity and alcohol abuse are other
ational Institute of Neurological Disorders and Stroke and Association Internationale pour
r dementia.
Fig. 2. Pathological changes found in stroke Subtypes I to III involving large artery and
small vessel diseases in elderly stroke survivors. A, Large infarcts (arrows) in the parietal
lobe of 80-year old woman with cognitive impairment. This fits the classification of
Subtype I in Fig. 1. B: Lacunes (arrow) and WM lesions in external capsule in the basal
ganglia of a 78-year-old man with cognitive impairment. Note also WM rarefaction in
the temporal limb (star symbol). C: Perivascular spaces (dilatation) and demyelination
in WM (Luxol fast blue stain). D, Microinfarct in the caudate with some perivascular
dilatation (HE, Haematoxylin and Eosin). E, Small infarct in the temporal pole (HE). C-E
are typical small lesions in subtype II. F, A microinfarct in the thalamus. Moderate gliosis
in the surrounding region is also evident. Thalamic infarcts can occur as 0.5 cm lacunes
in the coronal section in B. Magnification Bar: A and B = 2 cm; C, D and F = 50 μm,
E = 100 μm.
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[29]. Bilateral hippocampal or thalamic infarctions and unilateral tha-
lamic infarctions are other examples of strategically localised infarctions
that are reported to cause dementia (Fig. 1, subtype III). Strategic infarc-
tion dementia may be caused by damage to the components of Papez
(hippocampal memory loop) [30] or Yokovlev circuits. However, de-
mentia resulting from strategic infarctions may not take into account
the influence from other lesions [31].
In post-stroke cohorts, the presence of executive syndrome and de-
pression is the predictor of poor long-term survival rather than depres-
sion itself [32]. Dementia and depression also interactwith each other in
the post-stroke period [33]. If there is preceding dementia, stroke
worsens the cognitive impairment. This is called pre-stroke dementia
with possibility of co-existing neurodegenerative pathology as a cause
of dementia [34]. Progressive dementia without any symptomatic
stroke but with only radiologically proven cerebrovascular diseasesmay not be diagnosed with dementia after stroke because cerebrovas-
cular lesions such asWM changes and apparently silent lacunar infarcts
are common in demented elderly with mixed pathology consisting of
Alzheimer's disease (AD) and cerebrovascular disease.
Dementia associatedwith cerebrovascular diseases is clinically diag-
nosed using the widely accepted DSM IIIR or IV criteria. The apparent
“gold standard” for diagnosis has been based on the results of the exten-
sive neuropsychological examination, clinical presentation, and infor-
mation from a close relative as well as the usefulness of R-CAMCOG
[35] or the Montreal Cognitive Assessment (MoCA) [36–38]. Such
short screening tests although are useful for both clinical and research
purposes, their sensitivity is limited and there is no clear consensus as
towhich test is themost appropriate so somehave used both or devised
wide-ranging test batteries [27,34,39].
Dementia after stroke may incorporate different types of dementias
but these there is hardly any pathological confirmation for most of the
clinical or prospective studies [21,40] evenwhere there is strong contri-
bution of neurodegenerative disease. TheNewcastle CogFAST study [21]
incorporating pathological examination showed that almost 75% of de-
mented stroke survivors fit current criteria for VaD [22,29,41], whereas
the rest had mixed pathology with either Alzheimer type of lesions or
Lewy bodies. Consistent with these observations, Mok and colleagues
[42] have elegantly shown that 70% of the stroke survivors do not retain
AD-like Pittsburgh compound B binding suggesting classical neurode-
generative pathology is not amajor contributor to cognitive impairment
after stroke injury. Thus, majority of stroke survivors with an appropri-
ate clinical diagnosis of dementia and neuropsychometric assessment
develop VaD. It would be reasonable to assume that many of these sub-
jects will have small vessel disease type of pathology (Fig. 1, subtype II
and Fig. 2) although there may be some burden of small cortical infarcts
and microinfarcts [21,40].
4. Frequencies of impairment after stroke
As the risk of death from strokes has declined, the number of stroke
survivors with cerebral compromise and cognitive dysfunction has in-
creased. Stroke survivors are at increased risk of cognitive impairment
[21,43]. Meta-analysis of data from several studies yielded estimates
of 1-in-10 patients being demented prior to a first stroke, 1-in-10 devel-
oping new dementia soon after a first stroke, and over 1-in-3 being de-
mented after a recurrent stroke [44,45]. The development of cognitive
impairment and incident dementia after stroke appears relatively com-
mon following stroke [19,45]. While not to be confused with periods of
delirium as an immediate consequence after stroke injury [46,47], cog-
nitive decline following an index stroke could be insidious with the la-
tent appearance of dementia especially in patients with small cortical
and subcortical infarcts.
Cognitive impairment after stroke is a frequent but neglected conse-
quence compared to other neurological deficits such as sensory or
motor impairment [48]. However, not all strokes result in cognitive im-
pairment but stroke significantly increases the risk of dementia [49]. In
community-based studies with adjustment for age, the prevalence of
dementia in people with a history of stroke is ~30% with 3·5–5·8
times higher than in those who did not have any detectable stroke inju-
ry [50]. The incidence of dementia in older people with a longer follow-
up time increases from 10% at 1 year to 32% after 5 years [19]. The
pooled prevalence estimates of dementia after stroke less than one
year after the stroke ranged from 7.4% in population-based studies of
first-ever stroke, in which pre-stroke dementia was excluded, to 41.3%
(29.6–53.1) in hospital-based studies of recurrent stroke, where pre-
stroke dementia was included. The cumulative incidence of dementia
after the first year was slightly greater (3.0%, 1.3–4.7) per year in
hospital-based studies than expected on the basis of recurrent stroke
alone [45]. In the Newcastle CogFAST (cognitive function after stroke)
study, we reported that although 41% were stable and 50% improved
in cognition at 15 months, survivors who were dementia free at three
Table 2
Modifiable or treatable risk factors for dementia after stroke injury.
Risk factor Clinical features and targets for modification
Hypertension Both systolic and diastolic pressures increase risk;
N140/90 mm Hg
Atrial fibrillation Both chronic and paroxysmal AF confer risk of stroke. AF
involved in ~10% of all strokes; in N80 year olds it is
~36%. Anticoagulants including aspirin suggested but
they are not without risk. Not recommended for those
who develop dementia.
Diabetes mellitus Type
II
Risk of stroke can be independently increased by 1.8 to 6
fold. Strategies to reduce risk of stroke are focused in
reducing co-morbidity with hypertension.
Dyslipidaemia Elevated cholesterol and LDLs and lower HDLs increase
stroke. Consistent reduction of stroke risk by use of
statins but only marginally effective in dementia
Cardiac and Carotid
arterial diseases
Arterial stenosis or occlusion caused by atherosclerotic
plaques is well-known risks for stroke and cerebral
hypoperfusion. Both asymptomatic and symptomatic
arterial disease are associated with cognitive
impairment.
High homocysteine Elevated homocysteine (N13 mg/ml) is considered risk
for vascular disease related cognitive impairment but
not widely accepted. Diet folate supplementation can
lower homocysteine.
Obesity BMI of N25 and increased abdominal fat stroke
predictors of stroke risk. Body weight reduction reduces
risk of stroke.
Metabolic syndrome Cluster of modifiable subclinical and clinical conditions
including glucose tolerance, elevated blood pressure,
low HDL and abdominal obesity increases risk of stroke.
Aggressive strategy to reduce multiple components
would reduce risk.
Risk factors mostly associated with ischaemic stroke rather than dementia after stroke.
Data derived from several references: [141,142,146–150]. Among others chronic kidney
disease as amarker of vascular risk factors such as hypertension and diabetes is associated
with small vessel disease and cognitive impairment [151]. Cigarette smoking and exces-
sive alcohol consumptionmay also contribute to impairment by increasing stroke risk. Ab-
breviations: AF, atrial fibrillation; BMI, body mass index; HDL, high-density lipoprotein;
LDL, low-density lipoprotein.
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quently progress to delayed dementia [21]. In the parallel prospective
CogFAST- Nigeria study, 40% of older stroke survivors had cognitive im-
pairment without dementia and 8.4% were demented three months
after stroke [39]. Consistent with other studies, utilising the three
month design [52–54] before follow up, delayed dementia after stroke
was estimated to occur in at least 25% of the subjects with various risk
factors. In addition, the Helsinki study [55] has most recently reported
that up to 83% of stroke survivors show impairment in at least one
whereas 50% are impaired in multiple (N3) cognitive domains. Impor-
tantly, 71% of cases with good clinical recovery at 3 months still
exhibited cognitive impairment in memory, visuoconstructional or ex-
ecutive functions.
5. Risk factors for cognitive impairment after stroke
In tandem with the age-related increased incidence of stroke itself,
older age is the strongest risk factor for VCI and dementia after stroke
(Table 1). This is consistentwith the high incidence of stroke or cerebro-
vascular related dementia in the elderly [7,21]. In the CogFAST studies
[21,39], we found that the mean age of cognitively impaired subjects
was greater with expectedly lower CAMCOG scores than the non-
demented stroke subjects.
Hypertension is the most common modifiable risk factor for stroke.
Elevations in both systolic and diastolic blood pressures are associated
with increased risk of stroke and by extension stroke related dementia
(Table 2). In addition to severity of increased blood pressure, the dura-
tion of hypertensive state would be an important determinant of de-
mentia after stroke. When diabetes is present, hypertensives are even
at a higher risk of stroke and cognitive impairment [7]. Other risk factors
for dementia after stroke include recurrent stroke, pre-stroke depen-
dency, pre-stroke cognitive impairment, development of apathy or
quality of life with lower educational status and history of diabetes
mellitus [19,39,42,45,53,56,57]. Post stroke cognitive impairment is
then not surprisingly associated with poor functional outcomes.
Studies from general community populations indicate that VaD is
more frequent in males than in females, but most studies suggested
no substantial gender difference for the risk of dementia after stroke.
Recent findings suggest this is attributable to neuroprotective role ofTable 1
Risk factors of delayed dementia after stroke injury.
Demographic features Odds ratios
(p = 0.05–0.01)
Advanced age 6.6 for N65 years⁎;
1.05–1.2 per year
Genetic traits N1.5
Low education 2.5
Stroke characteristics
Transient ischaemic attack 1.83†
Recurrent stroke 2.3
Multiple infarcts 2.5
Strategically located infarcts NA
Stroke severity 2.5
Neuroimaging markers of brain lesions
Silent brain infarcts 1.8
White matter lesions 2.5
Medial temporal lobe atrophy 2.69–5.2††
Cerebral atrophy (global/temporal lobe atrophy) 2.6
Cerebral microbleeds NA‡
Data taken from several publications: [19,42,45,143,144]. Abbreviations: NA, not avail-
able; VCI, vascular cognitive impairment.
⁎ This study showed rather high risk with age [144].
† OR in post stroke patients with pre-stroke TIA less than 4weekswas determined to be
1.83 (95% CI 1.32-2.52).
†† ORs of post stroke amnestic VCI and MCI groups compared with non-amnestic VCI-
no dementia group [113].
‡ Cerebral microbleeds predicted frontal-executive impairment with OR 8.4 up to 5.7
years follow up [145].adiponectin because of the relatively steeper decline of serum
adiponectin levels associated with ageing in females than in males
[58]. Epileptic seizures, sepsis, cardiac arrhythmias and congestive
heart failure are listed as other risk factors of incident dementia after
stroke [59]. It is not surprising that atrial fibrillation and nephropathy
independently contribute to the risk in addition to older age, previous
mental decline, and stroke severity [52].
The risk of dementia is likely more when vascular comorbid condi-
tions occur. Thus, hypertension, atrial fibrillation, diabetes mellitus,
myocardial infarction, and congestive heart failure can often co-exist
in various proportions [19,42,59,60]. Consistent with this, our prospec-
tive longitudinal CogFAST study [21] showed that the presence of 3 or
more cardiovascular risk factors increased risk of dementia or death
by 4-fold in the elderly stroke survivors. These observations contrast
with a systematic review [61], where thefindings concluded that the ef-
fect of stroke on dementia incidence in the populationwas explained by
recurrent stroke rather than cardiovascular risk factors. A number of
studies has found significant effects of individual vascular risk factors
in both early and delayed dementia after stroke but have not examined
their cumulative effect. However, metabolic syndrome, a clustering of
several cardiovascular risk factors maywell affect dementia after stroke
through ‘metabolic–cognitive syndrome’ [62]. Another longitudinal
study [63] showed that patientswith dementia after stroke had a higher
prevalence of several vascular risk factors including hypertension, dia-
betes, atrial fibrillation, previous myocardial infarction and history of
transient ischaemic attack (Table 2). However, these associations were
not found in other studies with shorter follow up [52,53,64–66]. Inde-
pendent contribution of vascular risk factors or disorders to the devel-
opment of dementia following stroke still needs consensus [67]. Since
the rates of dementia after stroke may continue to rise in a relatively
919R.N. Kalaria et al. / Biochimica et Biophysica Acta 1862 (2016) 915–925linear fashion [45], they illustrate that stroke, vascular risk factors, or co-
existing neurodegenerative changes make the brain more vulnerable to
dementia in the longer term. The role of genetic influences in cognitive
impairment or dementia per se after stroke or VaD is not clear. So far
only one genome-wide association study involving 67 subjects, whode-
veloped incident VaD over amean follow-up of 9.3 years has identified a
single variant on the X chromosome near the androgen receptor gene
[68]. This locus has not been linked to other stroke manifestations and
the association with VaD, however, still remains to be independently
confirmed. Previous results reporting on the significance of specific can-
didate genes such as angiotensin converting enzymegene [69], alpha-1-
antichymotrypsin [69,70] or apolipoprotein E (APOE) gene [69,71,72] as
risk factors for dementia after stroke are not entirely in agreement. In
older stroke patients with early cognitive impairment, the presence of
anAPOE ԑ4 allelewas reported to be associatedwith greater progression
of cognitive decline [73]. However, as heritability of stroke may also in-
crease risk of impairment, it is noteworthy that several candidate genes
were recently identified to be associated with large artery and cardio-
embolic disease (Table 3). The majority of genetic variants identified
has been associated with specific subtypes of ischaemic stroke suggest-
ing that the subtypes bear distinct genetic compositions and pathophys-
iological mechanisms [74]. To date the association of single nucleotide
polymorphisms (SNPs) in only 5 loci seems to bemost consistently rep-
licated with the most robust significance (Table 3).
Variants in genes associatedwith familial small vessel diseases of the
brain [75] are also associatedwith cognitive impairment after ischaemic
or haemorrhagic injury (Table 3). Among these most recent develop-
ments include the NOTCH3 and HTRA1 genes linked to cerebral autoso-
mal dominant (CADASIL) and recessive (CARASIL) disorders. Both
common and rare SNPs in the NOTCH3 gene show increased risk of
age-related WM changes in hypertensive subjects [76]. Similarly,
seven variants of the HTRA1 gene were identified to be associated
with hereditary SVD of unknown aetiology [77]. Recently, three intronicTable 3
Common variants of widely confirmed genes associated with sporadic stroke phenotypes⁎.
Stroke
Type/vascular
disorder
Candidate
gene (or near
locus)
Chromosome
locus
Gene variants†† Pro
typ
CADASIL† NOTCH3 19p13.2-p13.1 Non-synonymous SNPs
(H170R, P496L, V1183M,
L1518M, D1823N and V1952M)
Tra
cell
rec
CARASIL† HTRA1 10q25.3-q26.2 Heterozygous variant R166L A se
pro
Small vessel
disease (with
ICH)†
COL4A2 rs9521732; rs9521733;
rs9515199 (intronic SNPs)
Col
Large artery
atherosclerosis
HDAC9 7p21.1 rs2107595 Unk
Large artery
atherosclerosis
TSPAN2 1p13.2 G allele at rs12122341 Unk
Large artery
atherosclerosis
SUPT3H/CDC5L 6p21.1 rs556621 Unk
Cardioembolism ZFHX3 16q22.3 rs879324 Unk
Cardioembolism PITX2 4q25 rs6843082 Unk
All strokes
(small
arteries)
ALDH2 12q24.12 rs10744777 Unk
Abbreviations: AF, atrial fibrillation; BM, basement membrane; CADASIL, cerebral autosomal d
cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopahty
acidosis, and stroke-like episodes; NICD, Notch intracellular domain; RVCL, retinal vasculopath
⁎ Several other gene variants of different stroke types and stroke-free white matter hyperin
approaches or genome-wide association studies. Data summarised from several references [78,1
blood coagulation system.
† Hereditary forms of cerebral small vessel disease (SVD) lead to cognitive impairment or de
autosomal dominant or recessive or X-linked monogenic disorders e.g. RVCL, Fabry's, MELAS.
†† SNPs, single nucleotide polymorphisms associated with SVD phenotypes [76,77].SNPs in the COL4A2 gene were identified to be associated with symp-
tomatic small vessel disease, particularlyWM disease and deep intrace-
rebral haemorrhage [78],
6. Neuroimaging determinants in relation to neuropathology
Neuroimaging has been very useful to recognise that a combination
or interaction of different types of brain lesion, including neurodegener-
ative markers, and preexisting underlying processing are players in the
development of cognitive decline after clinical stroke. Brain lesion cor-
relates of dementia after stroke include a combination of infarct features
(volume, site), the presence of WM changes (extent, location), as well
as brain atrophy [79]. However, strategic site lesion, baseline stroke se-
verity, greater severity of WM changes and medial temporal lobe atro-
phy appear the strongest contributors of subsequent impairment [42,
80–84]. In the 24 year Dijon study [63], the prevalence of dementia
after stroke associated with lacunar strokes was seven times higher
than other types of stroke including intracerebral haemorrhage. Pre-
stroke medial temporal lobe atrophy [85,86] or silent brain infarcts
and microbleeds, and extensive WM changes were associated with an
increased risk of post-stroke memory dysfunction, a prerequisite for
the diagnosis of dementia after stroke. Severe WM changes associated
with subcortical stroke injury in turnmay influence cortical greymatter
[87,88] to contribute to impairment. The presence of other pathologies
including AD-like changes is another factor that worsens cognition
and increase incident dementia after stroke or transient ischaemic at-
tack [34].
7. Mechanisms of cell death leading to dementia
Much of the current knowledge of the ischaemic injury cascade
comes from experimental studies. The cascade consists of a complex se-
ries of events which are highly heterogeneous [89] and evolve overtein
e/function
Predicted dysfunction(s) or pathology
nsmembrane
signalling
eptor
Aberrant cell–cell signalling, activates unfolded protein response and
impaired gene transcription (NICD)
rine
tease
Promote serine-protease-mediated cell death, suppress TGF-beta
expression
lagen IV Basement membrane proteins associated with complex structure.
COL4-related angiopathies are caused by mutations in
COL4A1/COL4A2
nown Function associated with large artery atherosclerosis
nown Gene close to member
of transmembrane 4 (tetraspanin) superfamily of proteins, which
mediate signal transduction to regulate cell development, activation,
growth, and motility. Associated with large artery
atherosclerosis-related stroke
nown Function associated with large artery atherosclerosis-related stroke
nown Function associated with AF, which common in elderly
nown Function associated with AF, which common in elderly
nown Function varied as gene associated with all ischemic stroke subtypes
ominant arteriopathy with subcortical infarcts and leukoencephalopathy [159]; CARASIL,
[160]; ICH, intracerebral haemorrhage; MELAS, mitochondrial encephalomyopathy, lactic
y with cerebral leukodystrophy.
tensities have been identified but not widely confirmed by comphrensive meta-analysis
52–158]. Some of these include genes involved in control of plasma homocysteine and the
mentia. To date there do not appear to be variants of genes associated with other rarer
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main stages include energy failure due to disruption of blood flow,
excitoxicity, calcium overloading, oxidative stress, blood- brain barrier
(BBB) dysfunction, microvascular injury, haemostatic activation, injury
- related inflammation and immune responses, and cell death involving
neurons, glia and endothelial cells. Microvascular damage and disrup-
tion of the BBB, which may occur days later, lead to vasogenic oedema
and can also cause haemorrhages. At the same time, the tissue may un-
dergo complex range of reparative and remodelling responses including
angiogenesis to limit damage and improve outcome. These events are
curtailed in ageing brains such that the parenchyma is irreparably dam-
aged which then contributes to cognitive dysfunction.
Experimental studies suggest neuronal death following ischaemic
injury is largely attributed to necrosis. However, recent developments
indicate that significant cell death occurs by apoptotic as well as hybrid
mechanisms (e.g. necroptosis) along an apoptosis–necrosis continuum.
While the infarcted core is necrotic be it macro- or microinfarction,
within the penumbra caspase-mediated apoptosis is activated although
secondary necrosis results from failure to implement the apoptotic sig-
nalling pathways fully, as they require energy. Ischaemic injury triggers
two general pathways of apoptosis. The intrinsic pathway originates
withmitochondrial release of cytochrome c and subsequent stimulation
of caspase-3whereas the extrinsic pathway is initiated by the activation
of cell surface death receptors, which belong to the tumour necrosis fac-
tor superfamily, by Fas ligand, resulting in the stimulation of caspase-8.
There is some evidence that ischaemic cell death may also be mediated
by autophagy, which is activated during cerebral ischaemia for the bulk
removal of damaged neuronal organelles and proteins [90,91]. Molecu-
lar markers of the autophagic process during ischaemic injury include
increased production of microtubule-associated protein 1 light chain 3
(LC3-II), Beclin-1, lysosome-associated membrane protein 2 and lyso-
somal cathepsin B. Oxidative and endoplasmic stresses in cerebral
ischaemia are proposed to be potent stimuli for autophagy in neu-
rons [92]. There is also cross-talk between pathways involved in
autophagy and apoptosis and both processes occur in parallel, as
suggested by upregulation of both autophagic and apoptotic
markers in the ischaemic penumbra [90]. It is not unlikely that autophagy
after ischaemic injury [93] is a contributor to parenchymal changes
leading to impairment.
Neuroinflammation and immunodepression are also associatedwith
stroke, ageing, and infection. These likely have a detrimental role in cog-
nitive function after stroke [94–97]. Diminished or impaired inflamma-
tory mechanisms are likely another factor in the pathways leading to
dementia. Thus, besides immunosenescence, cerebral atrophy is anoth-
er factor why reactive cells including microglia and astrocytes exhibit a
dampened cytokine response in the production of IL-6 and IL-8 in those
stroke subjects that develop dementia compared to thosewhodo not. In
contrast, C reactive proteinwas not altered between dementia and non-
dementia subjects. Strategies that enhance anti-inflammatory cytokines
and boost the neuroimmune system may be beneficial for preventing
cognitive dysfunction, especially after stroke [98].
Compared to neuroimaging correlates the pathological substrates
associated with dementia after stroke or VaD have generally lagged be-
hind. This is particularly true in defining those substrates associated
with executive dysfunction. There is selective atrophy (30–40%) of py-
ramidal cells in layers III andV of thedorsolateral prefrontal cortex com-
pared to the anterior cingulate and orbitofrontal cortices of the frontal
lobe in subjects with dementia after stroke, VaD and, of mixed and AD
versus normal ageing controls and those who did not have dementia
after stroke [99]. These findings indicated neuronal atrophy occurs irre-
spective of the presence of amyloid or neurofibrillary or tau pathology.
The neuronal volume changes were also related to cognitive dysfunc-
tion shown by lower total revised Cambridge Cognition Examination
(CAMCOG), orientation and memory scores and clinical dementia rat-
ings. In further morphometric analysis of the dorsolateral prefrontal
cortex, it was shown that neither diffuse cerebral atrophy norneocortical thickness explained the selective neuronal volume effects.
However, neurofilament protein SMI31 immunoreactivity was in-
creased in subjects with dementia after stroke and VaD compared to
non-demented stroke subjects and correlated with decreased neuronal
volumes in both dementia after stroke and VaD subjects [99]. These
findings possibly relate to causal relationship between incident subcor-
tical infarcts or acute infarcts and morphological alterations in connect-
ed cortical regions, which exhibit cortical thinning or atrophy [87,100].
Conceivably, secondary neurodegeneration within the cortical grey
matter may occur after myelin loss and axonal damage in the WM.8. Pathophysiology of the WM and the blood brain barrier
Constant perfusion of the WM by deep penetrating arterioles is
essential for functioning of axons and oligodendrocytes. Depending
on the duration and severity of ischaemic or oligaemic injury, several
features may be readily evident in the WM. These include activated
microglia, clasmatodendritic astrocytosis, myelin breakdown, pres-
ence of axonal bulbs and degeneration, reactivation and loss of oligo-
dendroglia. During subsequent (chronic) periods of arteriolar
changes, perivascular spacing and apoptotic oligodendroglia are
seen accompanied bydegeneration ofmyelin and expression of hypoxia
markers. [101].
WM hyperintensities as seen on brain T2-weighted or FLAIR mag-
netic resonance imaging (MRI) are associated with varying degrees of
cognitive dysfunction in stroke, cerebral small vessel disease and de-
mentia. The pathophysiologicalmechanismswithin theWMaccounting
for cognitive dysfunction remain unclear. Stroke patients with more se-
vere WM changes have an increased risk of recurrent strokes. Thus, the
presence and severity ofWM changes seen onMRImay be predictive of
post-stroke dementia [19,82,102,103]. However, WM hyperintensities
may not be predictive of subsequent decline in all stroke survivors
and clearly other anatomical substrates appear more involved [85,
102]. Ischemic WM changes are most prominent in the frontal lobe
[104] and appear linked with frontal -subcortical disconnection [27,
105]. The WM changes consist of myelin rarefaction with shrunken oli-
godendrocytes and axonal abnormalities resulting from vascular insuf-
ficiency and a chronic hypoxic state [106–108]. Independent effects of
WM changes in dementia among stroke patients needs to be verified
by simultaneously taking into account all other MRI findings as other
types of brain lesions, such as cerebral atrophy and silent infarcts are
strongly correlated with WM changes. Microstructural changes of nor-
mal appearingWM as evident in diffusion tensor imagingmay be a bet-
ter predictor of cognitive decline in patients with WM hyperintensities
[109]. It also apparent that the edge of WM hyperintensities is a predi-
lection site for lacunes, most of which typically occur proximal to pre-
existing WM hyperintensities with regard to the anatomical course of
perforating vessels. These observations highlight the concept of the
WM hyperintensity penumbra [110].
Recent clinicopathological studies [111] showed that post-stroke sur-
vivors who had exhibited greater frontal WM hyperintensities volumes
which predicted shorter time to dementia onset, consistently exhibited
disruption of gliovascular interactions and BBB damage. In contrast to
normal appearing glial fibrillary acid protein immunopositive (GFAP+)
astrocytes, the percentage of clasmatodendrocytes was increased by N2-
fold in demented compared to non-demented subjects and by 11-fold
in older normal controls versus young controls in the frontal WM. These
were associated with aberrant co-localization of aquaporin-4 in retracted
GFAP+ astrocytes with disrupted end-feet juxtaposed to microvessels.
High ratios of clasmatodendrocytes to total astrocytes in the frontal WM
were consistent with lower Mini-Mental State Examination and the re-
vised CAMCOG scores in demented subjects. Thus, clasmatodendrosis ap-
pears another pathological substrate, linked to WM hyperintensities and
frontal WM changes, which contributes to delayed dementia after stroke
injury [111].
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Medial temporal lobe and global atrophy are both shown to be asso-
ciatedwith dementia after stroke [19] (Table 1). If medial temporal lobe
atrophy is considered a marker of AD, the development of dementia
after stroke in subjects with medial temporal lobe atrophy may be
caused by the concomitant neurodegenerative process that was ongo-
ing in the preclinical phase at the time of stroke occurrence. Previous
studies found that in elderly stroke survivors, medial temporal lobe at-
rophy was associated with shorter time to dementia [86] but it was
more strongly associated with subsequent cognitive decline than were
WM changes [85], which suggested a greater role for Alzheimer-type
pathology than cerebrovascular lesions in the development of delayed
cognitive impairment after the onset of clinical stroke. This was further
supported by the findings that reductions in blood flow, assessed by ar-
terial spin labelling, in the posterior artery territories and in volumes of
the hippocampal formation were similar in dementia after stroke and
AD subjects [65,112]. In accordance with these findings, another study
showed that increasing severity of medial temporal lobe atrophy was
associated with amnestic VCI no dementia (OR = 2.69; 95% CI =
1.21–5.99) and amnestic MCI (OR = 5.20; 95% CI = 2.41–11.23) com-
pared to non-amnestic VCI no dementia in post stroke survivors [113].
Moreover, the impaired post stroke episodic memory function may be
caused by reduced medial temporal lobe functionality [114]. Significant
correlation between WM changes and medial temporal lobe atrophy
was similarly found in a cohort of African stroke survivors [57]. Howev-
er, WM changes in the frontal and parieto-occipital regions correlate
with hippocampal atrophy, suggesting that there is a tangible link be-
tween vascular pathology and hippocampal atrophy [115]. That such a
link exists, there is selective hippocampal neuronal shrinkage which
does not only appear to be an important substrate for AD but also de-
layed dementia after stroke in the absence of any neurodegenerative
pathology [116]. This is consistent with the findings in animal models
that long-termhypoperfusion does not require co-existing neurodegen-
erative changes to induce hippocampal atrophy [117] and demonstrates
the vascular basis for hippocampal neurodegeneration and dementia.
10. Silent brain infarcts, microbleeds and cerebral
amyloid angiopathy
Several studies have consistently reported that cerebral silent in-
farcts detectable with computed tomography or MRI were indepen-
dently predictive of dementia after stroke [118,119]. Silent infarcts
may be more important to the delayed onset of dementia in patients
with clinical stroke because presence of silent infarcts is associated
with dementia after stroke detected in the third year, but not in the sec-
ond year after the index stroke [120]. In addition,microbleeds are radio-
logical hallmarks of cerebral amyloid angiopathy (CAA) that can be
detected with the T2*-weighted gradient-echo sequence of MRI. CAA
may cause cognitive impairment because of multiple substrates,
which include cerebral microbleeds, microinfarcts and WM changes
(leukoaraiosis).WMpathology is quite common in CAA butWMchang-
es have not been consistently correlated with CAA [121–123]. CAA,
however, is a cause of cortical microinfarcts (50–500 μm in diameter)
that are invisible on conventional 1.5 and 3 Tesla MRI [124–126].
While observations on the occurrence of stroke and dementia after
stroke in patients with microbleeds are not generally available [127], a
recent study in a large cohort of patients in a memory clinic found a rel-
atively high frequency of microbleeds in patients with VaD (65%), AD
(18%), and mild cognitive impairment (20%) [128]. This clinic-based
study is consistent with the neuropathological observations, which
showed that severe CAA and cerebral cortical microinfarcts are in tan-
dem important substrates of cognitive decline [129]. Changes in the he-
modynamics such as hypotension in the presence of CAA may be
indicated as a key factor in the genesis of cortical watershed
microinfarcts [85,130].11. Cognitive dysfunction prior to stroke
The risk of dementia after stroke is increased in patients with pre-
stroke cognitive decline, with about one-third of patients meeting the
criteria for AD and two-thirds meeting the criteria for VaD [131]. This
has led to the formulation of the term “pre-stroke dementia” [131].
Preexisting brain structural changesmay have impact on the occurrence
of dementia after stroke. These preexisting changes are likely related to
different mechanisms possibly incorporating parallel processes i.e. neu-
rodegenerative and vascular that result in the development of dementia
[132]. Brain atrophy and medial–temporal lobe atrophy may underlie
AD pathology, while WM changes may be more prone to subcortical
VaD. However, as previously emphasised [133], there is an overlap be-
tween vascular and degenerative mechanisms responsible for the path-
ogenesis of VaD such that in the oldest old there is high burden ofmixed
pathology [107]. Only one single factor cannot explain the development
of dementia related to large-vessel pathology, as the aetiology is proba-
bly multi-factorial, where stroke characteristics (stroke type, volume,
number, location and severity) aswell as host factors such as comorbid-
ities contribute to the risk independently. In the majority of the cases,
several mechanisms interact to exceed the critical threshold for normal
cognition, and dementia subsequently occurs. Thus, evenmarginally in-
creased burden of amyloid and neurofibrillary pathology above normal
ageing but insufficient for pathological diagnosis of AD likely adds to the
tissue degenerative process leading to dementia after stroke. This im-
portant issue could be further investigated using positron emission to-
mography (PET) imaging for amyloid [134] or tau [135].
12. Preventive strategies
Anymeasure that reduces or controls vascular diseasewould be pre-
ventative for dementia after stroke [136]. In recent years, a variety of
lifestyle factors including diet and physical activity that reduce or
abate vascular disease has been highlighted for prevention of dementia.
These would all be equally applicable in the prevention of dementia
after stroke. Despite its high prevalence, the treatment options for de-
mentia after stroke are limited. In fact, patients with cognitive impair-
ment or dementia subsequent to stroke injury may often be less
treated with aspirin or warfarin than non-demented individuals [137].
There are no drugs so far approved for the treatment of VaD per se. Cho-
linesterase inhibitors and memantine may have a beneficial effect,
which may be due to co-existing AD pathophysiology [138]. As most
vascular risk factors and disorders aremodifiable (Table 2), understand-
ing the role of vascular risk factors in dementia is crucial for devising
strategies for the treatment of dementia after stroke [139]. Neverthe-
less, as dementing disorders, once established, are not curable, imple-
mentation of primary treatment of vascular disorders seems to be the
most promising for reducing the burden of not only dementia after
stroke but also dementia in general.
Stroke is related to two- to nine fold increase in risks of dementia
[43]; therefore, adequate primary prevention and neuroprotective in-
tervention after stroke occurrence or recurrent events [140] will have
enormous impact. As stated above hypertension is the most modifiable
risk factor for stroke. For primary prevention, trials involving various
classes of antihypertensives suggest any antihypertensive could be use-
ful to reduce risk [141]. For secondary prevention, the combination of
ACE inhibitors and diuretic agents has been recommended [142]. How-
ever, trials assessing secondary prevention usually exclude patients
with dementia. Results collected between 1995 and 2011 from the
community-based South London Stroke Register [139] showed that, in pa-
tientswith ischemic strokeswithout a history of atrialfibrillation, therewas
a significantly reduced risk of cognitive impairment associatedwith the use
of antihypertensives (relative risk, 0.7 for diuretics; 0.8 for angiotensin-
converting enzyme inhibitors; and0.7 for their combination)whenclinical-
ly indicated. In addition, there was a tendency of reduced risk of cognitive
impairment associated with the use of a combination of aspirin and
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tive effects against cognitive impairment were also observed in patients on
the combination of antihypertensives, antithrombotic agents, and lipid-
lowering drugs (relative risk, 0.55). Educational attainment has been
found to protect against cognitive impairment in numerous disorders in-
cluding MCI, AD and VaD [138]. Educational achievements together with
occupational complexity and social engagement constitute the ‘Cognitive
Lifestyle’ paradigm, which has been associated with a reduced long-term
risk of dementia and found to be associated with neurotrophic changes in
the prefrontal lobe consistent with a compensatory process. Physical activ-
ity and healthy diet including fish intake have also been shown to be pro-
tective against post-stroke dementia [39]. These rather modestly
inexpensive measures have immense implications for public vascular and
brain health especially in low resource settings.
13. Summary
Cognitive impairment after ischaemic stroke injury is common in
different populations. Although dementia after stroke is a clinical entity,
current neuroimaging and pathological studies suggest that majority of
older age-related dementia after stroke can be classed as VaD. Emerging
small vessel disease associated genetic traits, severe WM changes and
medial temporal lobe atrophy are important features in the develop-
ment of dementia after stroke injury. The well-established relationship
between vascular risk factors and dementia provides a rationale for the
implementation of interventions. Control of vascular disease risk and
prevention of recurrent strokes are obviously key to reducing the bur-
den of cognitive decline and dementia after stroke.
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